Biogen Inc (NASDAQ:BIIB) Pays $75 Million For PF-05251749

Most of the patients struggling with Parkinson’s and Alzheimer’s go through the most devastating conditions. This ranges from sleep disorders to agitation, and it is a good thing that Biogen Inc (NASDAQ:BIIB) wants to change things. The business guru is placing yet another bet on Alzheimer’s disease R&D).

Biogen’s bet

This has taken the form of paying Pfizer Inc (NYSE:PFE) upfront payment amounting to $75 million. A series of tests have been conducted among healthy volunteers, and the good thing was the development of PF-05251749.

The above candidate happens to be a CK1 inhibitor that has merited its status as a leading remedy. This product’s incredible abilities have been showcase by its abilities to regulate the circadian rhythms. The whole thing is about sparking about improvements in the neurological and the behavioral symptoms in patients struggling with diseases such as Alzheimer’s.

Pfizer has been focusing on the collection of clinical data with the major areas of focus being the safety of the drug and the mechanism of action.

Plans into the future

Biogen outlines that the product has the potential for further development. This was after taking a close look at data that was obtained by the scientists. The business guru says it doesn’t regret having to spend $75 million on the product. It adds that it is ready and willing to channel another $635 million towards further developments. It has already set in place its guiding commercialization milestones and promises that soon the drug will be added to its pipeline.

Biogen has spoken concerning the wake rhythm disorder associated with Parkinson’s and sundowning in Alzheimer’s. The company says that these are matters of great concern that need to be looked at more closely.

The business guru outlines that sundowning is the cause of a large number of patients experiencing confusion. As time progresses, they start experiencing anxiety.

It has also spoken about ISWRD, which it says has a trend of disrupting night sleep, which results in fatigue among the affect ted persons.

Biogen is glad that PF-05251749 has some desirable effects on the circadian rhythms. It terms this an important attribute towards dealing with ISWRD and sundowning.

Leave a comment

Your email address will not be published. Required fields are marked *